Article
Responses to the multitargeted MET/ALK/ROS1 inhibitor crizotinib and co-occurring mutations in lung adenocarcinomas with MET amplification or MET exon 14 skipping mutation.
Lung cancer (Amsterdam, Netherlands) - 1 Dec 2015
Jorge Susan E, Schulman Sol, Freed Jason A, VanderLaan Paul A, Rangachari Deepa, Kobayashi Susumu S, Huberman Mark S, Costa Daniel B
Abstract excerpt
INTRODUCTION: Genomic aberrations involving ALK, ROS1 and MET can be driver oncogenes in lung adenocarcinomas. Identification of tyrosine kinase inhibitors (TKIs) with activity against these tumors and of preclinical systems to model response are warranted. METHODS: We analyzed cases with lung adenocarcinomas for representative genomic aberrations, evaluated the response to the multitargeted MET/ALK/ROS1...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.